Helix BioPharma Management
Management criteria checks 2/4
Helix BioPharma's CEO is Thomas Mehrling, appointed in Apr 2025, has a tenure of 1.25 years. total yearly compensation is CA$342.23K, comprised of 37.8% salary and 62.2% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $47.27K. The average tenure of the management team and the board of directors is 1.3 years and 3.6 years respectively.
Key information
Thomas Mehrling
Chief executive officer
CA$342.2k
Total compensation
| CEO salary percentage | 37.82% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Apr 30 2026 | n/a | n/a | -CA$3m |
| Jan 31 2026 | n/a | n/a | -CA$4m |
| Oct 31 2025 | n/a | n/a | -CA$5m |
| Jul 31 2025 | CA$342k | CA$129k | -CA$5m |
Compensation vs Market: Thomas's total compensation ($USD240.70K) is below average for companies of similar size in the US market ($USD658.93K).
Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.
CEO
Thomas Mehrling
Dr. Thomas Mehrling is Chief Medical Officer of Helix BioPharma Corp. from March 5, 2025 and serves as its Chief executive Officer since April 10, 2025. Dr. Mehrling was Chief Executive Officer of Release...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Corporate Secretary | 4.3yrs | CA$104.73k | 0.84% $ 642.0k | |
| CEO & Chief Medical Officer | 1.3yrs | CA$342.23k | 0.062% $ 47.3k | |
| Chief Financial Officer | 1.1yrs | CA$243.77k | no data | |
| Chief Operating Officer | 1.3yrs | CA$232.24k | no data | |
| Chief Technology Officer | 1.3yrs | CA$213.60k | no data | |
| General Counsel | less than a year | no data | no data | |
| Director of Communications | 1.3yrs | no data | no data | |
| Corporate Secretary | less than a year | no data | no data |
Experienced Management: HBPC.F's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Corporate Secretary | 4.3yrs | CA$104.73k | 0.84% $ 642.0k | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.3yrs | CA$1.42k | 0.55% $ 419.1k | |
| Independent Director | 3.6yrs | CA$1.42k | no data | |
| Independent Director | 2.9yrs | no data | no data |
Experienced Board: HBPC.F's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 23:58 |
| End of Day Share Price | 2026/05/18 00:00 |
| Earnings | 2026/04/30 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Helix BioPharma Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahu Demir | NOBLE Capital Markets, Inc. |